MetaCap

Biomea Fusion (BMEA) vs Mereo BioPharma Group (MREO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biomea Fusion (BMEA) has outperformed Mereo BioPharma Group (MREO) over the past year, losing 41.5% versus a loss of 85.6%. Over five years, MREO leads with a -86.3% price change compared with -95.2% for BMEA. Biomea Fusion is the larger company by market cap ($41.7 million vs $41.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BMEA-41.51%MREO-85.56%
+136%+19%-97%
Nov 21, 20251 yearNov 20, 2026
BMEA-94.67%MREO-87.06%
+298%+92%-113%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BMEA versus MREO key metrics
MetricBMEAMREO
Share price$0.5744$0.26
Market cap$41.75M$41.52M
1-day change-2.38%-5.45%
YTD return-53.68%-37.65%
1-year return-41.51%-85.56%
5-year return-95.21%-86.32%
EPS (TTM)$-0.10$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$500.00K
Net income (latest FY)$-61.80M$-41.88M
Operating margin—-8021.40%
Net margin—-8375.60%
52-week high$2.24$2.37
52-week low$0.45$0.20
Distance from 52-week high-74.32%-89.03%
Analyst consensusbuynone
Avg. price target upside+1118.66%+653.85%
Average volume2.22M1.24M
Shares outstanding72.68M159.70M
Employees3739
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BMEA has outperformed MREO by 44.0 percentage points over the past year.

About Biomea Fusion

BMEA stock →

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees

About Mereo BioPharma Group

MREO stock →

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.

Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees

BMEA vs MREO FAQ

Which is bigger, Biomea Fusion or Mereo BioPharma Group?

Biomea Fusion (BMEA) is larger, with a market capitalization of $41.75M compared with $41.52M for Mereo BioPharma Group (MREO).

Which stock has performed better over the past year, BMEA or MREO?

BMEA returned -41.51% over the past 12 months, compared with -85.56% for MREO (price return, excluding dividends). Past performance does not predict future results.

Are Biomea Fusion and Mereo BioPharma Group in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons